Clinical Trial Update: A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of glasdegib (PF-04449913) with azacitidine in untreated myelodysplastic syndrome, acute myeloid leukemia, and chroni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Glasdegib (glasdegib)

Snippet

Sponsor: Pfizer | Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia | Phase 1 | Status: COMPLETED | Results posted: 2021-03-05